What is the Stemcell Institute Inc. stock price forecast?

Stemcell Institute Inc. is currently trading at ¥669. View real-time AI analysis on Alpha Lenz.

What is Stemcell Institute Inc. insider trading activity?

View the latest insider trading data for Stemcell Institute Inc. on Alpha Lenz.

What is Stemcell Institute Inc.'s P/E ratio?

Stemcell Institute Inc.'s P/E ratio is 17.8.

Stemcell Institute Inc.

JPX · 7096

¥669-4(-0.59%)Market closed

Ask about Stemcell Institute Inc.'s future dividend policy...

Alpha Chat Insight

“Stemcell Institute Inc. trades at a P/E of 17.8 (fair value) with solid ROE of 14.5%. 3Y revenue CAGR of 14.6% highlights clear growth momentum.”

Ask for details →

Company Overview

Stemcell Institute Inc. operates within the healthcare and biotechnology sectors, focusing primarily on stem cell research and the development of regenerative treatments. The company is dedicated to utilizing cutting-edge scientific techniques to harness the potential of stem cells in treating a variety of diseases and medical conditions. Stemcell Institute Inc. is pivotal in advancing medical treatments that seek to repair or replace damaged cells, tissues, or organs, solidifying its role in transforming healthcare practices. Their work involves collaboration with research institutions and hospitals to innovate therapeutic solutions that cater to chronic and degenerative illnesses. The significance of the company in the market is underscored by its specialized focus on regenerative medicine, contributing to its status as an important player in the biotechnological landscape and influencing future developments in patient care and treatment methodologies.

Websitehttps://www.stemcell.co.jp

SectorHealthcare

IndustryBiotechnology

Employees117

Company Statistics

FY 2025

Profile

¥6,851,603,640Market Cap

¥2,679,175,000Revenue

0.00Shares Out

117Employees

Margins

63.16%Gross

20.84%EBITDA

15.62%Operating

21.12%Pre-Tax

14.40%Net

Valuation

17.76P/E

2.61P/B

2.56EV/Sales

7.47EV/EBITDA

-64.00P/FCF

Growth (CAGR)

14.56%Rev 3Yr

9.83%Rev 5Yr

22.63%Op Inc 3Yr

1.82%Op Inc 5Yr

42.36%Net Inc 3Yr

6.81%Net Inc 5Yr

Returns

5.49%ROA

14.50%ROE

8.07%ROIC

Financial Health

¥3,200,846,000Cash & Cash Equivalents

¥1,672,245,000Net Debt

185.44%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Stemcell Institute Inc. trades at a P/E of 17.8 (fair value) with solid ROE of 14.5%. 3Y revenue CAGR of 14.6% highlights clear growth momentum.”

Ask for details →

Frequently Asked Questions

Stemcell Institute Inc. (ticker: 7096) is a company listed on JPX in the Healthcare sector (Biotechnology). It has approximately 117 employees. Market cap is $6.9B.

The current price is 669 with a P/E ratio of 17.76x and P/B of 2.61x.

ROE is 14.50% and operating margin is 15.62%. Annual revenue is $2.7B.